NCT06076694View on ClinicalTrials.gov

Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 26, 2022

Primary Completion Date

September 20, 2022

Study Completion Date

September 20, 2022

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

TNP-2198

Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days

DRUG

Rabeprazole Sodium

Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days

DRUG

Amoxicillin

Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

TenNor Therapeutics (Suzhou) Limited

INDUSTRY